Opinion|Videos|November 17, 2026

Psychiatric History and Family Planning in Treatment Selection

Matthew A. Gubens, MD, MS, presents a 40-year-old working mother with a history of depression to explore how patient factors shape first-line therapy in ROS1-positive non-small cell lung cancer (NSCLC).

Matthew A. Gubens, MD, MS, presents a 40-year-old working mother with a history of depression to explore how patient factors shape first-line therapy in ROS1-positive non-small cell lung cancer (NSCLC). Estelamari Rodriguez, MD, MPH, has moved away from repotrectinib in young patients because neurocognitive effects interfere with daily activities and can worsen preexisting psychiatric conditions, which complicates management in community practice. She counsels families to report subtle changes and holds the drug to confirm causality. Ana I. Velázquez Mañana, MD, MSc, notes that repotrectinib has more described mood disorders and that more than 30% of patients develop significant dizziness, so she counsels patients about driving. For young parents and adults, she selects taletrectinib for its more favorable neurotoxicity profile, with the goal of returning patients to their prior function. Dr. Velázquez Mañana also emphasizes fertility preservation referral before treatment, noting that all currently approved ROS1 inhibitors carry labeling warnings against pregnancy.


Related to this article